Vanda Pharmaceuticals (VNDA) Reports Q2 EPS of $0.21, Revenues Beat; Offers FY19 HETLIOZ & Fanapt Combined Sales Outlook
Tweet Send to a Friend
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.21, versus $0.00 reported last year. Revenue for the quarter came in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
